Posted inHealth Care
Policy Overhaul Needed: Impact of the Food Industry on Global Brain Health
In a recent study published by the Baker Institute, researchers propose several policy solutions that can effectively target…
Posted inGlobal News
Walgreens to pay San Francisco $229 million for opioid crisis
Walgreens Reaches $230 Million Settlement in San Francisco Opioid Lawsuit Walgreens to pay San Francisco nearly $230 million…
Posted inHealth Care
Accelerating value in healthcare
Reprinted with permission from Geisinger Health. This piece was originally published in Beckers Hospital Review on May 16,…
Posted inHealth Care
How providers are adapting to post-PHE clinical care
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The first day Sterling…
Posted inGlobal News
EpiPen alternative: FDA may approve first nasal spray for anaphylaxis
Share on PinterestIn the case of a severe allergic reaction, study results showed that nasally administered epinephrine had…
Posted inHealth Care
MN Democrats say how to control health care costs, but medical providers have resisted
Efforts by Minnesota Democrats to impose new rules on the health care sector have met aggressive lobbying from…
Posted inHealth Care
Six Key Moments from the Ways and Means Committee Hearing on Healthcare Price Transparency – House Committee on Ways and Means
WASHINGTON DC Price transparency can reduce costs and improve health care outcomes for families, workers and small businesses,…
Posted inHealth Care
Post-PHE Hospice Settlement: Preparing for the Reinstated Volunteer Requirement
The return of volunteering requirements is one of the regulatory changes being implemented with the end of the…
Posted inHealth Care
Senators are examining the largest Medicare Advantage plans on how algorithms account for denial of care
StSenators warned the country's largest Medicare Advantage insurers in a hearing Wednesday that they must abide by Medicares…
Posted inGlobal News
First-Line Eftilagimod Alpha Plus Pembrolizumab Generates OS Benefits in PD-L1+ NSCLC
Eftilagimod alfa (efti; IMP321) plus pembrolizumab (Keytruda) provided overall survival (OS) benefit compared with historical controls when given…